Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Brian Shuster will join the ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

NYSE:SOLV) The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...